Trials / Conditions / Hemophilia A With Inhibitor

Hemophilia A With Inhibitor

30 registered clinical trials studyying Hemophilia A With Inhibitor — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction NCT07158606	Versiti Blood Health	Phase 4
Recruiting	Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophil NCT06864975	Runhui WU	Phase 4
Terminated	The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC C NCT06568302	ApcinteX Ltd	Phase 3
Completed	Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem NCT06357572	Enzyre B.V.	—
Active Not Recruiting	Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors NCT06312475	Suzhou Alphamab Co., Ltd.	Phase 3
Recruiting	ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibit NCT05888870	Institute of Hematology & Blood Diseases Hospital, China	Phase 4
Completed	SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment NCT06010953	Jiangsu Gensciences lnc.	Phase 1 / Phase 2
Completed	A Phase I of SS109 in Hemophilia A or and B With Inhibitors NCT05651061	Jiangsu Gensciences lnc.	Phase 1
Recruiting	Pharmacokinetic-guided Dosing of Emicizumab NCT06320626	Kathelijn Fischer	Phase 4
Terminated	The Hemophilia Inhibitor Eradication Trial NCT04303572	Margaret Ragni	Phase 3
Recruiting	SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors NCT04647227	American Thrombosis and Hemostasis Network	Phase 4
Terminated	Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders NCT04548791	Catalyst Biosciences	Phase 1 / Phase 2
Terminated	Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B NCT04489537	Catalyst Biosciences	Phase 3
Completed	Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibit NCT04789954	AryoGen Pharmed Co.	EARLY_Phase 1
Active Not Recruiting	Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior In NCT04684940	BioMarin Pharmaceutical	Phase 1 / Phase 2
Unknown	Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia. NCT04768699	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1
Active Not Recruiting	A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab NCT04205175	Children's Hospital Los Angeles	Phase 4
Completed	An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Fa NCT04723693	Haemnet	—
Unknown	A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip NCT04592692	Ascension Healthcare Development Limited	Phase 2
Completed	Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia NCT04072237	Catalyst Biosciences	Phase 1
Unknown	The Safety of Emicizumab SC Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors NCT04805801	JW Pharmaceutical	—
Completed	rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A NCT03951103	Swedish Orphan Biovitrum	—
Completed	ATHN 7: Hemophilia Natural History Study NCT03619863	American Thrombosis and Hemostasis Network	—
Completed	ATHN 8: Previously Untreated Patients (PUPs) Matter Study NCT03818529	American Thrombosis and Hemostasis Network	—
Completed	Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and NCT03407651	Catalyst Biosciences	Phase 2
Terminated	INdividualized ITI Based on Fviii(ATE) Protection by VWF NCT03204539	University of California, Davis	Phase 4
Completed	Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven NCT03372993	AryoGen Pharmed Co.	—
Unknown	Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China NCT03598725	Beijing Children's Hospital	Phase 4
Unknown	Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibi NCT02554526	Nara Medical University	—
Completed	Hemophilia Inhibitor Genetics Study (HIGS) NCT00166387	Skane University Hospital	—